StockIQStockIQ.tech

EssilorLuxottica Société anonyme (EL.PA) Stock Analysis

--

Free AI-powered analysis and research for EssilorLuxottica Société anonyme stock

Sector: Healthcare

EL.PA snapshot

Data as of 4 Nov 2026 close. Updated daily.

Last close
189.10 EUR (+2.63%)
52-week range
138.30 – 323.80
Position in range
27%
1-year change
-40.2%
Market cap (USD)
$97.4B
P/E (trailing)
34.1
RSI (14-day)
72
vs 200-day average
+3.5%
MACD
Above signal line
StockIQ score: 44/100 · Mixed signals

EssilorLuxottica Société anonyme scores 44/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 27% of its 52-week range, down 40.2% over the past year. Latest reported figures show a profit margin of 8.5%, return on equity of 6.7% and revenue growth of +5.7%.

What is driving the score
  • Strong Uptrend: +12
  • MACD Bullish: +8
  • High P/E (34.1): -10
  • Low Liquidity (0.89 Current Ratio): -10
  • Above MA200: +4
  • Severe Underperformance (-40.2% over 1 year): -10

Automated, general information only – not financial advice. Scores can be wrong. How the score works

Full EL.PA report

EssilorLuxottica Société anonyme (EL.PA) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze EL.PA Now →

📰 Latest Update

S&P upgrades EssilorLuxottica to ’A+’ on strength of medtech pivot

S&P has upgraded EssilorLuxottica (EL.PA) to an 'A+' rating, citing the company's successful pivot towards the medtech sector. This upgrade reflects increased confidence in the company's growth potential and financial stability, which could attract more institutional investors. For investors, this rating enhancement may lead to improved stock performance and lower borrowing costs for the company.

Read full article →

History

People also watch

REGN
Regeneron Pharmaceuticals Inc.
--
LLY
Eli Lilly and Company
--
UNH
UnitedHealth Group Inc.
--
JAZZ
Jazz Pharmaceuticals plc
--
AGIO
Agios Pharmaceuticals, Inc.
--